Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.

Vaccine effectiveness against severe illness was 43% among children with underlying conditions and 53% among those without.

Nasal vaccines offer convenience and another option for those wary of needles, but traditional vaccines are best for young ...

Moderna, Inc. vs. Novavax, Inc.: cost cuts, vaccine pipeline catalysts, and valuations. Click for this comparison of NVAX and ...

Leadership cites "uncertainties," but experts say the agency is the one sowing confusion ...